Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

Sandra Torres Galván; María Flores-López; Pablo Romero-Sanchiz; Nerea Requena-Ocaña; Oscar Porras-Perales; Raquel Nogueira-Arjona; Fermín Mayoral; Pedro Araos; Antonia Serrano; Roberto Muga; Francisco Javier Pavón; Nuria García-Marchena; Fernando Rodríguez de Fonseca

doi:10.1038/s41598-021-93075-1

Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

Sandra Torres Galván, María Flores-López, Pablo Romero-Sanchiz, Nerea Requena-Ocaña, Oscar Porras-Perales, Raquel Nogueira-Arjona, Fermín Mayoral, Pedro Araos, Antonia Serrano, Roberto Muga, Francisco Javier Pavón, Nuria García-Marchena, Fernando Rodríguez de Fonseca

School of Psychology

Research output: Contribution to journal › Article › peer-review

Abstract

Granulocyte colony–stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = − 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls ( p < 0.05), specifically in the cocaine subgroup ( p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls ( p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.

Original language	English
Article number	13629 (2021)
Pages (from-to)	13629
Number of pages	1
Journal	Scientific Reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-93075-1
Publication status	Published - 1 Jul 2021

Access to Document

10.1038/s41598-021-93075-1Licence: CC BY

https://doi.org/10.1038/s41598-021-93075-1 http://www.nature.com/articles/s41598-021-93075-1Licence: CC BY

Cite this

Galván, S. T., Flores-López, M., Romero-Sanchiz, P., Requena-Ocaña, N., Porras-Perales, O., Nogueira-Arjona, R., Mayoral, F., Araos, P., Serrano, A., Muga, R., Pavón, F. J., García-Marchena, N., & de Fonseca, F. R. (2021). Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. Scientific Reports, 11(1), 13629. Article 13629 (2021). https://doi.org/10.1038/s41598-021-93075-1

@article{e82c07faf79b40d8a6d33e326cb9d89d,

title = "Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder",

abstract = "Granulocyte colony–stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = − 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls ( p < 0.05), specifically in the cocaine subgroup ( p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls ( p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.",

author = "Galv{\'a}n, {Sandra Torres} and Mar{\'i}a Flores-L{\'o}pez and Pablo Romero-Sanchiz and Nerea Requena-Oca{\~n}a and Oscar Porras-Perales and Raquel Nogueira-Arjona and Ferm{\'i}n Mayoral and Pedro Araos and Antonia Serrano and Roberto Muga and Pav{\'o}n, {Francisco Javier} and Nuria Garc{\'i}a-Marchena and {de Fonseca}, {Fernando Rodr{\'i}guez}",

year = "2021",

month = jul,

day = "1",

doi = "10.1038/s41598-021-93075-1",

language = "English",

volume = "11",

pages = "13629",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

Galván, ST, Flores-López, M, Romero-Sanchiz, P, Requena-Ocaña, N, Porras-Perales, O, Nogueira-Arjona, R, Mayoral, F, Araos, P, Serrano, A, Muga, R, Pavón, FJ, García-Marchena, N & de Fonseca, FR 2021, 'Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder', Scientific Reports, vol. 11, no. 1, 13629 (2021), pp. 13629. https://doi.org/10.1038/s41598-021-93075-1

Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder. / Galván, Sandra Torres; Flores-López, María; Romero-Sanchiz, Pablo et al.
In: Scientific Reports, Vol. 11, No. 1, 13629 (2021), 01.07.2021, p. 13629.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Plasma concentrations of granulocyte colony-stimulating factor (G-CSF) in patients with substance use disorders and comorbid major depressive disorder

AU - Galván, Sandra Torres

AU - Flores-López, María

AU - Romero-Sanchiz, Pablo

AU - Requena-Ocaña, Nerea

AU - Porras-Perales, Oscar

AU - Nogueira-Arjona, Raquel

AU - Mayoral, Fermín

AU - Araos, Pedro

AU - Serrano, Antonia

AU - Muga, Roberto

AU - Pavón, Francisco Javier

AU - García-Marchena, Nuria

AU - de Fonseca, Fernando Rodríguez

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Granulocyte colony–stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = − 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls ( p < 0.05), specifically in the cocaine subgroup ( p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls ( p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.

AB - Granulocyte colony–stimulating factor (G-CSF) has raised much interest because of its role in cocaine addiction in preclinical models. We explored the plasma concentrations of G-CSF in patients diagnosed with substance use disorder (SUD) and highly comorbid psychiatric disorders. In particular, we investigated the association between G-CSF concentrations and comorbid major depressive disorder (MDD) in patients with cocaine and alcohol use disorders (CUD and AUD, respectively). Additionally, patients with MDD but not SUD were included in the study. Three hundred and eleven participants were enrolled in this exploratory study: 136 control subjects, 125 patients with SUD (SUD group) from outpatient treatment programs for cocaine (N = 60, cocaine subgroup) and alcohol (N = 65, alcohol subgroup), and 50 patients with MDD but not SUD (MDD group) from primary-care settings. Participants were assessed based on DSM-IV-TR criteria, and a blood sample was collected to examine the plasma concentrations of G-CSF. G-CSF concentrations were negatively correlated with age in the entire sample (r = − 0.233, p < 0.001) but not in the patients with MDD. G-CSF concentrations were lower in patients with SUD than in controls ( p < 0.05), specifically in the cocaine subgroup ( p < 0.05). Patients with SUD and comorbid MDD had lower G-CSF concentrations than patients with SUD but not comorbid MDD or controls ( p < 0.05). In contrast, patients with MDD but not SUD showed no differences compared with their controls. The negative association between G-CSF concentrations and age in the sample was not observed in patients with MDD. G-CSF concentrations were decreased in patients with SUD and comorbid MDD but not in patients with MDD. Therefore, G-CSF may be useful to improve the stratification of patients with dual diagnosis seeking treatment. Further investigation is needed to explore the impact of sex and type of drug on the expression of G-CSF.

U2 - 10.1038/s41598-021-93075-1

DO - 10.1038/s41598-021-93075-1

M3 - Article

SN - 2045-2322

VL - 11

SP - 13629

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 13629 (2021)

ER -